Let the data speak to you

Journal of Practical Psychiatry and Behavioral Health

Volumn 3, Issue 1, 1997, Pages 45-48

  Preshorn, Sheldon H ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b University of Kansas School of Medicine Wichita Psychiatric Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 7844242686     PISSN: 10765417     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of paroxetine and other specific serotonin reuptake inhibitors on cytochrome P450IID6 activity in human liver microsomes. Br J Clin Pharmacol 1991;32:658P-9P.
2. Otton SV, Ball SE, Cheung SW, Inaba T, Sellers EM. Comparative inhibition of the polymorphic enzyme CYP2D6 by venlafaxine and other 5HT uptake inhibitors. Clin Pharmacol Ther 1994;55:141.
3. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P-450 2D6 activity. Clin Pharmacol Ther 1993;53:401-9.
4. Skjelbo E, Brosen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992;34:256-61.
5. von Moltke LL, Greenblatt DJ, CotreauBibbo MM, Duan SX, Harmatz JS, Shader RI. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants and by quinidine and ketoconazole: A model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994;268:1278-83.
6. Brosen K. Are pharmacokinetic drug interactions with the SSRIs an issue? Int Clin Psychopharmacol 1996;11(suppl 1):23-7.
7. Ereshefsky L. Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol 1996;16(3) (suppl2):37-50.
8. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: Interpretation of their interactions with selective serotonin reuptake inhibitors: Part I. J Clin Psychopharmacol 1996;16:273-85.
9. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: Interpretation of their interactions with selective serotonin reuptake inhibitors: Part II. J Clin Psychopharmacol 1996;16(5):345-55.
10. Shader RI, von Moltke LL, Schmider J, Harmatz JS, Greenblatt DJ. The clinician and drug interactions: An update (editoral). J Clin Psychopharmacol 1996;16(3):197-201.
11. DeVane CL. Dr. DeVane replies. J Clin Psychiatry 1996;57(5):225-6.
12. Preskorn SH. Clinical pharmacology of selective serotonin reuptake inhibitors. Caddo, OK: Professional Communications, Inc; 1996.